Total Payments
$96,138
2024 Payments
$24,146
Companies
19
Transactions
83
Medicare Patients
1,226
Medicare Billing
$253,730
Payment Breakdown by Category
Consulting$68,146 (70.9%)
Research$19,297 (20.1%)
Other$5,000 (5.2%)
Travel$2,041 (2.1%)
Food & Beverage$1,611 (1.7%)
Education$43.00 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $68,146 | 40 | 70.9% |
| Unspecified | $19,297 | 4 | 20.1% |
| Honoraria | $5,000 | 2 | 5.2% |
| Travel and Lodging | $2,041 | 9 | 2.1% |
| Food and Beverage | $1,611 | 27 | 1.7% |
| Education | $43.00 | 1 | 0.0% |
Payments by Type
General
$76,841
79 transactions
Research
$19,297
4 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $19,161 | 5 | $0 (2024) |
| Travere Therapeutics, Inc. | $17,227 | 18 | $0 (2023) |
| Aurinia Pharma U.S., Inc. | $11,746 | 9 | $0 (2024) |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | $11,732 | 4 | $0 (2024) |
| Retrophin, Inc. | $7,812 | 14 | $0 (2019) |
| GlaxoSmithKline, LLC. | $5,225 | 3 | $0 (2022) |
| Amgen Inc. | $3,525 | 7 | $0 (2023) |
| Genentech, Inc. | $3,525 | 2 | $0 (2022) |
| Horizon Therapeutics plc | $3,000 | 1 | $0 (2022) |
| Alexion Pharmaceuticals, Inc. | $2,750 | 1 | $0 (2020) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $24,146 | 11 | Aurinia Pharma U.S., Inc. ($9,538) |
| 2023 | $15,282 | 17 | Travere Therapeutics, Inc. ($11,315) |
| 2022 | $27,103 | 15 | Novartis Pharmaceuticals Corporation ($10,275) |
| 2021 | $12,733 | 10 | Otsuka Pharmaceutical Development & Commercialization, Inc. ($4,995) |
| 2020 | $6,661 | 11 | Travere Therapeutics, Inc. ($3,829) |
| 2019 | $6,312 | 13 | Retrophin, Inc. ($6,312) |
| 2018 | $3,857 | 3 | Otsuka Pharmaceutical Development & Commercialization, Inc. ($2,357) |
| 2017 | $45.12 | 3 | Merck Sharp & Dohme Corporation ($45.12) |
All Payment Transactions
83 individual payment records from CMS Open Payments — Page 1 of 4
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/31/2024 | F. Hoffmann-La Roche AG | Gazyva (Biological) | — | In-kind items and services | $820.27 | Research |
| Study: Gazyva for the treatment of MN • Category: BioOncology | ||||||
| 11/21/2024 | Aurinia Pharma U.S., Inc. | LUPKYNIS (Drug) | Consulting Fee | Cash or cash equivalent | $3,600.00 | General |
| Category: LUPUS NEPHRITIS | ||||||
| 10/25/2024 | Apellis Pharmaceuticals, Inc. | — | Consulting Fee | Cash or cash equivalent | $1,080.00 | General |
| 09/30/2024 | F. Hoffmann-La Roche AG | Gazyva (Biological) | — | In-kind items and services | $616.24 | Research |
| Study: Gazyva for the treatment of MN • Category: BioOncology | ||||||
| 09/19/2024 | Novartis Pharmaceuticals Corporation | — | Food and Beverage | In-kind items and services | $125.55 | General |
| 09/16/2024 | Otsuka Pharmaceutical Development & Commercialization, Inc. | — | Consulting Fee | Cash or cash equivalent | $4,380.00 | General |
| 07/08/2024 | Novartis Pharmaceuticals Corporation | — | — | Cash or cash equivalent | $7,585.34 | Research |
| Study: Research Publication/ Writing Support | ||||||
| 06/21/2024 | Aurinia Pharma U.S., Inc. | LUPKYNIS (Drug) | Food and Beverage | In-kind items and services | $113.33 | General |
| Category: LUPUS NEPHRITIS | ||||||
| 06/17/2024 | Aurinia Pharma U.S., Inc. | LUPKYNIS (Drug) | Consulting Fee | Cash or cash equivalent | $2,100.00 | General |
| Category: LUPUS NEPHRITIS | ||||||
| 04/05/2024 | Aurinia Pharma U.S., Inc. | LUPKYNIS (Drug) | Consulting Fee | Cash or cash equivalent | $3,600.00 | General |
| Category: LUPUS NEPHRITIS | ||||||
| 04/02/2024 | Aurinia Pharma U.S., Inc. | LUPKYNIS (Drug) | Food and Beverage | In-kind items and services | $124.80 | General |
| Category: LUPUS NEPHRITIS | ||||||
| 12/12/2023 | Travere Therapeutics, Inc. | — | Consulting Fee | Cash or cash equivalent | $4,000.00 | General |
| 12/12/2023 | Travere Therapeutics, Inc. | — | Travel and Lodging | In-kind items and services | $402.15 | General |
| 11/14/2023 | GENZYME CORPORATION | FABRAZYME (Biological) | Food and Beverage | In-kind items and services | $17.24 | General |
| Category: Genetic Disease | ||||||
| 11/03/2023 | NOVARTIS PHARMACEUTICALS CORPORATION | — | Food and Beverage | In-kind items and services | $74.99 | General |
| 10/27/2023 | Amgen Inc. | TAVNEOS (Drug) | Consulting Fee | Cash or cash equivalent | $500.00 | General |
| Category: Inflammation | ||||||
| 10/11/2023 | Travere Therapeutics, Inc. | — | Food and Beverage | In-kind items and services | $114.89 | General |
| 08/29/2023 | GENZYME CORPORATION | — | Food and Beverage | In-kind items and services | $36.31 | General |
| 07/28/2023 | Aurinia Pharma U.S., Inc. | LUPKYNIS (Drug) | Education | In-kind items and services | $43.00 | General |
| Category: LUPUS NEPHRITIS | ||||||
| 06/16/2023 | Apellis Pharmaceuticals, Inc. | — | Consulting Fee | Cash or cash equivalent | $1,080.00 | General |
| 06/08/2023 | Aurinia Pharma U.S., Inc. | LUPKYNIS (Drug) | Food and Beverage | In-kind items and services | $115.08 | General |
| Category: LUPUS NEPHRITIS | ||||||
| 05/30/2023 | Travere Therapeutics, Inc. | — | Consulting Fee | Cash or cash equivalent | $2,500.00 | General |
| 05/09/2023 | Travere Therapeutics, Inc. | — | Travel and Lodging | In-kind items and services | $181.82 | General |
| 05/03/2023 | Amgen Inc. | TAVNEOS (Drug) | Consulting Fee | Cash or cash equivalent | $500.00 | General |
| Category: Inflammation | ||||||
| 05/02/2023 | Travere Therapeutics, Inc. | — | Consulting Fee | Cash or cash equivalent | $4,000.00 | General |
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| PUBLICATION SUPPORT PROVIDED IN CONNECTION WITH HEOR RESEARCH | Novartis Pharmaceuticals Corporation | $10,275 | 1 |
| Research Publication/ Writing Support | Novartis Pharmaceuticals Corporation | $7,585 | 1 |
| Gazyva for the treatment of MN | F. Hoffmann-La Roche AG | $1,437 | 2 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 8 | 287 | 528 | $322,700 | $69,787 |
| 2022 | 6 | 283 | 470 | $280,840 | $59,355 |
| 2021 | 8 | 370 | 658 | $301,630 | $72,567 |
| 2020 | 8 | 286 | 537 | $215,240 | $52,021 |
Total Patients
1,226
Total Services
2,193
Medicare Billing
$253,730
Procedure Codes
30
All Medicare Procedures & Services
30 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 92 | 175 | $129,500 | $27,783 | 21.5% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 72 | 157 | $68,030 | $16,249 | 23.9% |
| 99291 | Critical care, first 30-74 minutes | Facility | 2023 | 11 | 56 | $56,120 | $10,954 | 19.5% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 25 | 25 | $20,950 | $5,026 | 24.0% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 32 | 32 | $25,600 | $4,908 | 19.2% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 22 | 48 | $13,920 | $3,247 | 23.3% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 15 | 15 | $8,100 | $1,453 | 17.9% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2023 | 18 | 20 | $480.00 | $168.00 | 35.0% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 71 | 143 | $105,820 | $21,353 | 20.2% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 111 | 208 | $81,120 | $18,433 | 22.7% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 44 | 44 | $35,200 | $7,735 | 22.0% |
| 99291 | Critical care, first 30-74 minutes | Facility | 2022 | 12 | 25 | $25,000 | $4,921 | 19.7% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2022 | 24 | 24 | $19,920 | $4,613 | 23.2% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 21 | 26 | $13,780 | $2,302 | 16.7% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2021 | 128 | 320 | $124,800 | $30,360 | 24.3% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Office | 2021 | 51 | 97 | $63,500 | $16,237 | 25.6% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 70 | 102 | $50,360 | $11,761 | 23.4% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2021 | 27 | 27 | $21,600 | $4,999 | 23.1% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Office | 2021 | 26 | 26 | $21,580 | $4,744 | 22.0% |
| 99222 | Initial hospital inpatient care, typically 50 minutes per day | Facility | 2021 | 19 | 19 | $10,260 | $2,319 | 22.6% |
| 99221 | Initial hospital inpatient care, typically 30 minutes per day | Facility | 2021 | 21 | 21 | $8,610 | $2,009 | 23.3% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2021 | 28 | 46 | $920.00 | $138.00 | 15.0% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2020 | 125 | 329 | $120,680 | $30,799 | 25.5% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2020 | 41 | 41 | $32,800 | $7,711 | 23.5% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Office | 2020 | 30 | 42 | $21,420 | $4,950 | 23.1% |
About Dr. Andrew Bomback, M.D
Dr. Andrew Bomback, M.D is a Nephrology healthcare provider based in New York, New York. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 05/04/2007. The National Provider Identifier (NPI) number assigned to this provider is 1013129816.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Andrew Bomback, M.D has received a total of $96,138 in payments from pharmaceutical and medical device companies, with $24,146 received in 2024. These payments were reported across 83 transactions from 19 companies. The most common payment nature is "Consulting Fee" ($68,146).
As a Medicare-enrolled provider, Bomback has provided services to 1,226 Medicare beneficiaries, totaling 2,193 services with total Medicare billing of $253,730. Data is available for 4 years (2020–2023), covering 30 distinct procedure/service records.
Ad
Practice Information
- Specialty Nephrology
- Location New York, NY
- Active Since 05/04/2007
- Last Updated 08/24/2011
- Taxonomy Code 207RN0300X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1013129816
Products in Payments
- LUPKYNIS (Drug) $11,746
- BENLYSTA (Biological) $5,225
- TOLVAPTAN (Drug) $2,268
- Tavneos (Drug) $2,025
- TAVNEOS (Drug) $1,500
- PURIFIED CORTROPHIN GEL (Drug) $1,475
- Gazyva (Biological) $1,437
- Veltassa (Drug) $81.94
- JANUVIA (Drug) $45.12
- FABRAZYME (Biological) $17.24
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Nephrology Doctors in New York
Dr. Gerald Appel, M.d, M.D
Nephrology — Payments: $842,842
Nephrology $842,842
Dr. Richard Chan, Md, MD
Nephrology — Payments: $525,489
Nephrology $525,489
Dr. Steven Coca, D.o., M.s, D.O., M.S
Nephrology — Payments: $388,012
Nephrology $388,012
Dr. Jai Radhakrishnan, M.d, M.D
Nephrology — Payments: $243,935
Nephrology $243,935
Dr. David Bernard, Md, MD
Nephrology — Payments: $235,726
Nephrology $235,726
Dr. Girish Nadkarni, Md, MD
Nephrology — Payments: $217,113
Nephrology $217,113